Overview

A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of Gefapixant (AF-219/MK-7264)

Status:
Completed
Trial end date:
2015-05-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to: determine the effect of stomach pH on the multiple dose pharmacokinetics (PK) of gefapixant (AF-219); assess the effect of multiple doses of gefapixant on various sensory assessments; and, assess the safety and tolerability of gefapixant.
Phase:
Phase 1
Details
Lead Sponsor:
Afferent Pharmaceuticals, Inc.
Collaborator:
Celerion
Treatments:
Omeprazole